Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23213094 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Condition: Carcinoma, Renal Cell
Intervention: Drug: foretinib (formerly GSK1363089 or XL880)

Indicates status has not been verified in more than two years